Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam Running Out Of Tamiflu To Treat Spreading Bird Flu

This article was originally published in PharmAsia News

Executive Summary

Vietnam's Ministry of Health says it has run out of effective Tamiflu just as the nation faces an increase in human cases of avian influenza. The stock at the National Institute of Infectious and Tropical Diseases was donated by Taiwan in 2005 and is now outdated, according an official. The ministry said it is using Vietnam-produced setavimin as a temporary substitute while it searches for more supplies of Tamiflu, the only drug proven effective against the bird flu. The nation has recorded more than 100 cases of H5N1 bird flu in humans. (Click here for more

You may also be interested in...



Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel